| Name | Title | Contact Details |
|---|---|---|
Kevin Vass |
Chief Financial Officer | Profile |
Molly Mendoza |
Vice President, Talent | Profile |
Joseph Jahnke |
Chief Financial Officer | Profile |
Lark Health is the leading virtual chronic disease management and prevention platform. Lark helps people stay healthy and in control of their conditions, such as Diabetes, Prediabetes, Cardiovascular Disease, and Anxiety from the comfort of their homes.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Inflexxion Inc is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Newton Upper Falls, MA. To find more information about Inflexxion Inc, please visit www.inflexxion.com
XIFIN, Inc. is an innovative software and services company dedicated to optimizing the economics of healthcare. The company`s cloud-based technology and business intelligence platform links healthcare stakeholders in the delivery and reimbursement of care, optimizing both business and patient outcomes and providing informed, streamlined diagnostic and business decision-making.
WebOps is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.